Juno Deal Gives Rosemont Access To Canada
Partnership Will Bring Range Of New Oral Liquids To Canadian Market
Juno Pharmaceuticals has struck a deal that will see it act as the exclusive distributor for UK-based Rosemont’s oral liquid medicines in Canada.
You may also be interested in...
After shutting down its trial for a leukemia conditioning agent due to a patient death, Magenta’s review of strategic alternatives concludes with a combination with complement inhibitor-focused Dianthus.
Pediatric and geriatric patients are continuing to struggle to access liquid-dose amoxicillin in Canada, prompting the health regulator to issue an emergency import authorization to local firm Juno Pharmaceuticals.
A year on from being spun-out of Perrigo and acquired by private equity, liquid generics specialist Rosemont Pharmaceuticals has revealed new details of the UK-based firm’s operations.